Top Page
4basebio UK Societas
(LSE:4BB)
4basebio UK Societas (4BB) vs. iShares MSCI United Kingdom ETF (EWC)
4basebio UK Societas Business Overview & Revenue Model
4basebio UK Societas Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 933.00K | 506.00K | 268.00K | 338.00K | 462.00K |
| Gross Profit | 630.00K | 340.00K | 239.00K | 269.00K | 274.00K |
| EBITDA | -10.97M | -7.34M | -5.41M | -3.21M | -346.00K |
| Net Income | -12.33M | -7.67M | -5.15M | -3.23M | -719.00K |
Balance Sheet | |||||
| Total Assets | 44.73M | 11.92M | 11.69M | 14.70M | 17.81M |
| Cash, Cash Equivalents and Short-Term Investments | 34.60M | 3.07M | 4.35M | 9.59M | 15.00M |
| Total Debt | 15.22M | 10.46M | 3.35M | 1.76M | 1.72M |
| Total Liabilities | 18.35M | 12.41M | 4.57M | 3.01M | 2.35M |
| Stockholders Equity | 26.38M | -492.00K | 7.12M | 11.70M | 15.46M |
Cash Flow | |||||
| Free Cash Flow | -12.31M | -7.67M | -6.64M | -4.25M | -1.87M |
| Operating Cash Flow | -10.74M | -6.18M | -4.70M | -2.74M | -1.02M |
| Investing Cash Flow | -1.57M | -1.49M | -1.94M | -1.51M | 1.45M |
| Financing Cash Flow | 43.87M | 6.42M | 1.24M | -467.00K | 14.43M |
4basebio UK Societas Technical Analysis
4basebio UK Societas Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | £128.53M | 16.37 | 69.08% | 6.41% | 0.49% | -9.52% | |
56 Neutral | £281.32M | 8.19 | 15.04% | ― | 1231.50% | ― | |
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
51 Neutral | £1.57B | ― | -26.01% | ― | 22.03% | 20.01% | |
46 Neutral | £93.40M | ― | 167.16% | ― | -100.00% | -23.91% | |
39 Underperform | £137.04M | ― | -95.28% | ― | 84.39% | -41.02% | |
| ― | $925.35M | ― | -66.23% | ― | ― | ― |
4basebio UK Societas Corporate Events
4basebio PLC announced the appointment of Dr. Manja Hermina Elisabeth Maria Boerman as Executive Chair of the Company, following an investment by Fort Aggregator LP, a Patient Square Capital platform. This appointment marks a significant board change, with Dr. Boerman bringing over 20 years of biopharmaceutical leadership experience to the role. The change in leadership is expected to support 4basebio’s ambition to accelerate commercial growth and enhance its platform, positioning the company as a preferred partner for high-quality synthetic DNA solutions.
4basebio UK Societas, a UK-based company, has announced a change in the breakdown of its voting rights. DELPHI Unternehmensberatung Aktiengesellschaft, based in Heidelberg, Germany, has adjusted its holdings, resulting in a slight decrease in its voting rights from 33.013180% to 32.985507%. This change signifies a minor shift in shareholder influence within the company, which may impact future decision-making processes.
4basebio UK Societas, a UK-based company, has announced a change in the breakdown of its voting rights. Wilhelm K. T. Zours, a major shareholder, now holds 32.985508% of the voting rights, slightly down from a previous position of 33.013179%. This adjustment in voting rights reflects a minor shift in shareholder influence, potentially impacting future company decisions and strategies.
4basebio PLC announced the results of its Annual General Meeting, where most resolutions were passed, except for Resolutions 14 to 16, which were withdrawn for amendments and will be reintroduced later. This decision reflects the company’s ongoing efforts to refine its strategic direction and maintain its position in the biotechnology industry, potentially impacting stakeholders by ensuring alignment with evolving market and regulatory demands.
4basebio PLC has announced the exercise of EMI options by two employees, resulting in the issuance of 13,000 new ordinary shares at an exercise price of £1.18 per share, raising £15,340 in total. These shares are set to be admitted to trading on AIM, with the total number of ordinary shares in issue rising to 15,509,393. This development is significant for shareholders as it impacts the total voting rights and may require them to notify changes in their shareholding under the Financial Conduct Authority’s rules.
4basebio UK Societas, a UK-based company, has announced a change in its major holdings. Wilhelm K. T. Zours has increased his voting rights in the company to 33.013179% from a previous 32.764383%, indicating a significant stake in the company. This change in holdings reflects an acquisition or disposal of voting rights, which may influence the company’s strategic decisions and impact stakeholders.
4basebio UK Societas, a UK-based company, has announced a change in its major holdings. DELPHI Unternehmensberatung Aktiengesellschaft, based in Heidelberg, Germany, has increased its voting rights in 4basebio to 33.01% from a previous 32.76%. This acquisition of voting rights indicates a strategic move by DELPHI Unternehmensberatung to strengthen its influence within the company, potentially impacting 4basebio’s future decisions and strategies.
4basebio PLC reported significant growth in 2024, doubling its DNA sales revenue and securing a £40 million equity investment to support its expansion plans. The company achieved several milestones, including supplying synthetic DNA for vaccine trials, obtaining a GMP manufacturing license, and forming a Strategic Advisory Board. These developments position 4basebio as a leader in the synthetic DNA market, with expectations of continued revenue growth and innovation in 2025.